Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-26T05:33:50.342Z Has data issue: false hasContentIssue false
  • English
  • Français

Role of plasma asymmetric dimethyl-L-arginine levels in detection of pulmonary hypertension in children with CHD

Published online by Cambridge University Press:  28 June 2018

Marwa Farag ,
Doaa El Amrousy ,
Hesham El-Serogy  and
Amr Zoair
Marwa Farag
Affiliation:
Pediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt
Doaa El Amrousy*
Affiliation:
Pediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt
Hesham El-Serogy
Affiliation:
Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt
Amr Zoair
Affiliation:
Pediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt
*
Author for correspondence: Professor D. El Amrousy, Assistant Professor of Pediatrics, Tanta University Hospital, El motasem street No. 6, Tanta, Egypt. Tel: +201 278 155 283; Fax: +204 032 80477; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

The objectives of this study were to evaluate the plasma levels of asymmetric dimethyl-L-arginine in children with pulmonary hypertension due to CHD before and after treatment with sildenafil and to evaluate its diagnostic and prognostic value as a biomarker in such children.

Methods

A total of 60 children with CHD and 30 healthy control children matched for age and sex were recruited. Children with CHD were divided into two equal groups: the normal pulmonary pressure group (n=30) and the pulmonary hypertension group (n=30). Children with pulmonary hypertension were treated with sildenafil and were followed up for 6 months. Clinical data, haemodynamic parameters, echocardiographic examination, and asymmetric dimethyl-L-arginine levels were evaluated before and after treatment.

Results

Asymmetric dimethyl-L-arginine levels were significantly higher in patients with pulmonary hypertension than in those with CHD-only or the control group, and this increase was positively correlated with increased severity of pulmonary hypertension. Asymmetric dimethyl-L-arginine levels, mean pulmonary artery pressure, and pulmonary vascular resistance were significantly decreased after treatment with sildenafil. Moreover, asymmetric dimethyl-L-arginine level was significantly lower in patients who responded to sildenafil treatment compared with those who did not. At a cut-off point of more than 0.85 nmol/ml, asymmetric dimethyl-L-arginine has a sensitivity of 83% and a specificity of 80% to diagnose pulmonary hypertension-CHD. Asymmetric dimethyl-L-arginine has a sensitivity of 100% and a specificity of 94% to predict poor prognosis in pulmonary hypertension-CHD children at a cut-off point of 1.3 nmol/ml.

Conclusion

Asymmetric dimethyl-L-arginine level has a good diagnostic and prognostic value as a biomarker in children with pulmonary hypertension-CHD and can be used for following up patients with pulmonary hypertension and predicting response to treatment.

Keywords

Asymmetric dimethyl-L-argininepulmonary hypertension-CHDprognosisdiagnosis
Type
Original Article
Information
Cardiology in the Young , Volume 28 , Issue 9 , September 2018 , pp. 1163 - 1168
Check for updates
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Cite this article: Farag M, El Amrousy D, El-SerogyH, Zoair A. (2018) Role of plasma asymmetric dimethyl-L-arginine levels in detection of pulmonary hypertension in children with CHD. Cardiology in the Young28: 1163–1168. doi: 10.1017//S1047951118001026

References

1. D’Alto, M, Mahadevan, VS. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir Rev 2012; 21: 328–337.Google Scholar
2. D’Alto, M, Romeo, E, Argiento, P, et al. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. Heart 2010; 96: 1475–1479.CrossRefGoogle ScholarPubMed
3. Galie‘, N, Hoeper, MM, Humbert, M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493–2537.Google Scholar
4. Janda, S, Shahidi, N, Gin, K, et al. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart 2011; 97: 612–622.CrossRefGoogle ScholarPubMed
5. Foris, V, Kovacs, G, Tscherner, M, Olschewski, A, Olschewski, H. Biomarkers in pulmonary hypertension: what do we know? Chest 2012; 144: 274–283.Google Scholar
6. Böger, RH. Asymmetric dimethy-l-arginine, and endogenous inhibitor of nitric oxide synthase, explains the ‘L-arginine paradox’ and acts as a novel cardiovascular risk factor. J Nutr 2004; 134: 2842S–2847SS.Google Scholar
7. Fang, Z, Huang, YH, Tang, L, Hu, X, Shen, X, Tang, J, Zhou, S. Asymmetric Dimethyl-L-Arginine is a biomarker for disease stage and follow-up of pulmonary hypertension associated with congenital heart disease. Pediatric Cardiology 2015; 36: 1062–1069.CrossRefGoogle ScholarPubMed
8. Sanli, C, Oguz, D, Olgunturk, R, et al. Elevated homocysteine and Asymmetric Dimethyl Arginine levels in pulmonary hypertension associated with congenital heart disease. Pediatr Cardiol 2012; 33: 1323–1331.Google Scholar
9. Pengfei, C, Yiyuan, H, Zhenfei, F, Xinqun, H, Xiangqian, S, Shenghua, Z. Clinical value of ADMA in patients with pulmonary arterial hypertension combination with congenital heart disease. J Cent South Univ (Med Sci) 2017; 42: 35–40.Google Scholar
10. Gorenflo, M, Zheng, C, Werle, E, Fiehn, W, Ulmer, HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001; 37: 489–492.Google Scholar
11. Galie, N, Hoeper, MM, Humbert, M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–1263.Google Scholar
12. Fisher, MR, Forfia, PR, Chamera, E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615–621.CrossRefGoogle ScholarPubMed
13. Galie, N, Ghofrani, HA, Torbiciki, A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Eng J Med 2005; 353: 2148–2157.CrossRefGoogle ScholarPubMed
14. Kielstein, JT, Bode-Böger, SM, Hesse, G, et al. Asymmetrical dimethy-l-arginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005; 25: 1414–1418.Google Scholar